SCHEMBL267181

SCHEMBL267181

Cc1cc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2cccnc2)oc1C

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.56
MEN1 O00255 7/20 0.56
POLB P06746 4/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 2/20 0.56
PABPC1 P11940 1/20 0.56
GAA P10253 2/20 0.50
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
KLF5 Q13887 1/20 0.46
IDE P14735 1/20 0.45
LDHA P00338 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267182 1.00 KMT2A (0.56) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL268756 0.89 KMT2A (0.51) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL268755 0.89 KMT2A (0.51) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL268290 0.89 ALDH1A1 (0.49) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL266478 0.89 MAPT (0.54) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL268291 0.89 ALDH1A1 (0.49) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL266477 0.89 MAPT (0.54) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL266291 0.84 KMT2A (0.55) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL266292 0.84 KMT2A (0.55) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL267642 0.83 KMT2A (0.57) KMT2AMEN1POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KMT2A 4564/4885MEN1 1194/4885POLB 3843/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KMT2A 4603/4885MEN1 1638/4885POLB 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.